These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37085137)

  • 41. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
    Di Ciaula A; Passarella S; Shanmugam H; Noviello M; Bonfrate L; Wang DQ; Portincasa P
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship.
    Karkucinska-Wieckowska A; Simoes ICM; Kalinowski P; Lebiedzinska-Arciszewska M; Zieniewicz K; Milkiewicz P; Górska-Ponikowska M; Pinton P; Malik AN; Krawczyk M; Oliveira PJ; Wieckowski MR
    Eur J Clin Invest; 2022 Mar; 52(3):e13622. PubMed ID: 34050922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes.
    Igoudjil A; Massart J; Begriche K; Descatoire V; Robin MA; Fromenty B
    Toxicol In Vitro; 2008 Jun; 22(4):887-98. PubMed ID: 18299183
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Deranged hepatocyte intracellular Ca
    Ali ES; Rychkov GY; Barritt GJ
    Cell Calcium; 2019 Sep; 82():102057. PubMed ID: 31401389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Models of non-Alcoholic Fatty Liver Disease and Potential Translational Value: the Effects of 3,5-L-diiodothyronine.
    Grasselli E; Canesi L; Portincasa P; Voci A; Vergani L; Demori I
    Ann Hepatol; 2017; 16(5):707-719. PubMed ID: 28809727
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.
    Boland ML; Oldham S; Boland BB; Will S; Lapointe JM; Guionaud S; Rhodes CJ; Trevaskis JL
    World J Gastroenterol; 2018 Apr; 24(16):1748-1765. PubMed ID: 29713129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mitochondrial metabolism and calcium homeostasis in the development of NAFLD leading to hepatocellular carcinoma.
    Bhowmick S; Singh V; Jash S; Lal M; Sinha Roy S
    Mitochondrion; 2021 May; 58():24-37. PubMed ID: 33581332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting Mitochondria for the Prevention and Treatment of Nonalcoholic Fatty Liver Disease: Polyphenols as a Non-pharmacological Approach.
    Zapata J; Castro-Sepulveda M; Soto-Alarcon S; Alvarez D; Bustamante A; Villarroel G; Gallardo A; Garcia-Diaz DF; Valenzuela R; Echeverria F
    Curr Med Chem; 2023; 30(26):2977-2995. PubMed ID: 36214303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease.
    Stacchiotti A; Favero G; Lavazza A; Golic I; Aleksic M; Korac A; Rodella LF; Rezzani R
    PLoS One; 2016; 11(1):e0148115. PubMed ID: 26824477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Novel Nutraceuticals Mixture Improves Liver Steatosis by Preventing Oxidative Stress and Mitochondrial Dysfunction in a NAFLD Model.
    Sangineto M; Bukke VN; Bellanti F; Tamborra R; Moola A; Duda L; Villani R; Romano AD; Serviddio G
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33671262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protective effect of the Y220C mutant p53 against steatosis: good news?
    Gori M; Barbaro B; Arciello M; Maggio R; Viscomi C; Longo A; Balsano C
    J Cell Physiol; 2014 Sep; 229(9):1182-92. PubMed ID: 24395441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk.
    Jiang L; Yang M; Li X; Wang Y; Zhou G; Zhao J
    J Clin Endocrinol Metab; 2018 Nov; 103(11):3974-3985. PubMed ID: 30053055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Pyrroloquinoline Quinone on Lipid Metabolism and Anti-Oxidative Capacity in a High-Fat-Diet Metabolic Dysfunction-Associated Fatty Liver Disease Chick Model.
    Qiu K; Zhao Q; Wang J; Qi GH; Wu SG; Zhang HJ
    Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33535680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genistein and 17β-Estradiol Protect Hepatocytes from Fatty Degeneration by Mechanisms Involving Mitochondria, Inflammasome and Kinases Activation.
    Farruggio S; Cocomazzi G; Marotta P; Romito R; Surico D; Calamita G; Bellan M; Pirisi M; Grossini E
    Cell Physiol Biochem; 2020 Apr; 54(3):401-416. PubMed ID: 32330379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The relationship between the opening of mitochondrial permeability transition pores of cultured hepatocytes with their apoptoses in a non-alcoholic fatty liver disease model].
    Chen DF; Wang CH
    Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):837-9. PubMed ID: 18073067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway.
    Kohli R; Pan X; Malladi P; Wainwright MS; Whitington PF
    J Biol Chem; 2007 Jul; 282(29):21327-36. PubMed ID: 17540768
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Bae S; Lee YH; Lee J; Park J; Jun W
    Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558538
    [No Abstract]   [Full Text] [Related]  

  • 59. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease.
    Lee J; Park JS; Roh YS
    Arch Pharm Res; 2019 Nov; 42(11):935-946. PubMed ID: 31571145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway.
    Li M; Xu C; Shi J; Ding J; Wan X; Chen D; Gao J; Li C; Zhang J; Lin Y; Tu Z; Kong X; Li Y; Yu C
    Gut; 2018 Dec; 67(12):2169-2180. PubMed ID: 28877979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.